Evaluation of Membrane Lung Function in High-altitude Regions

Status Recruiting

Clinical Trial Summary

Over the last 20 years, extracorporeal membrane oxygenation (ECMO) has been used to support adult patients with respiratory or cardiac failure who are unlikely to survive conventional treatment methods. ECMO circuit, pump, and oxygenator technology improvements permit safer perfusion for extended periods. The prolonged use of an ECMO circuit increases the risk of membrane lung (ML) dysfunction. The ML is responsible for taking in oxygen and removing carbon dioxide. The non-biologic surface of the ML triggers inflammatory and coagulation pathways, resulting in the formation of blood clots, breakdown of fibrin, and activation of white blood cells, which ultimately leads to ML dysfunction. Coagulation and fibrinolysis activation can cause systemic coagulopathy or hemolysis, and the deposition of blood clots can block blood flow. Moreover, the accumulation of moisture in the gas phase and the buildup of protein and cellular debris in the blood phase may contribute to shunt and dead-space physiology, respectively, impairing the exchange of gases. These three categories-hematologic abnormalities, mechanical obstruction, and inadequate gas exchange-account for most ML exchanges. Worsening oxygenation during ECMO should prompt quantification of oxygen transfer. ML exchange is indicated when the ML can no longer meet the patient's oxygen demand. The partial pressure of Post-ML arterial oxygen less than 200 mmHg is the most important consideration in making this decision. In some high-altitude regions of China, ECMO treatment is also routinely conducted. The experiences above are derived from low-altitude areas, and whether they apply in high-altitude regions is still being determined. This study aimed to explore the significantly lower post-membrane oxygen partial pressure in high-altitude regions compared to low-altitude areas.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Altitude Sickness
Extracorporeal Membrane Oxygenation
High Altitude

Clinical Trial Details

NCT number	NCT06152744
Study type	Observational
Source	Beijing Chao Yang Hospital
Contact	Hua Yang, Dr.
Phone	+8618601342030
Email	xuanben1985@163.com
Status	Recruiting
Phase
Start date	December 5, 2023
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03685383` - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation	N/A
Not yet recruiting	`NCT05106491` - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients	N/A
Recruiting	`NCT05699005` - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO	Phase 1
Recruiting	`NCT05444764` - PREdiCtIon of Weanability, Survival and Functional outcomEs After ECLS
Completed	`NCT05038943` - Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation	N/A
Not yet recruiting	`NCT05341687` - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Recruiting	`NCT03766282` - Pharmacokinetics in Extracorporeal Membrane Oxygenation
Completed	`NCT03355625` - Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
Completed	`NCT01521195` - Oxygen Consumption In Critically Ill Children	N/A
Recruiting	`NCT04620070` - ON-SCENE Initiation of Extracorporeal CardioPulmonary Resuscitation During Refractory Out-of-Hospital Cardiac Arrest	N/A
Recruiting	`NCT06062212` - Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Recruiting	`NCT05730114` - Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
Completed	`NCT05154071` - Impact of the Implementation of a Referral Veno-venous Extracorporeal Membrane Oxygenation Centre on Mortality
Recruiting	`NCT04536272` - Reduced Anticoagulation Targets in ECLS (RATE)	Phase 3
Completed	`NCT05693051` - Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Completed	`NCT03764319` - Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO	N/A
Recruiting	`NCT05762029` - Treatment of Extracorporeal Membrane Oxygenation in Severe Poisoning
Completed	`NCT02995811` - Characterising Changes in Muscle Quantity and Quality in Patients Requiring ECMO Oxygen During Critical Illness
Recruiting	`NCT04754854` - Reduction of Blood Recirculation in Veno-Venous ECMO

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.